Researchers at the Massachusetts Institute of Technology (MIT) in Cambridge, United States, developed a new experimental strategy that allows a drug against
Artifacts access the interior of the cartilage of the joints and regenerate it. The advance is tested in rats and is a step forward to achieve a treatment that slows the progression of the disease, for which there is no cure.
Arthrosis consists of a progressive degeneration of the cartilage of the joints due to aging or injuries. This pathology affects 300 million people worldwide and does not reverse, because the cartilage is a texture that can not be regenerated. According to this, the patients can choose to introduce a prosthesis in the affected lock or follow a pharmacological treatment, but to resist it is that it is
Very hard to access the cartilage.
Most drugs are removed from the joints before they can have an effect or they can not enter the cartilage where the cells that produce it – the chandrosites – are found so they can not carry their functions.
The researchers were led by looking for a strategy to overcome this disadvantage. They designed a nanocarrier: a molecule that acts as a vehicle capable of being introduced
Inside the cartilage and take a drug to the chandrosites. The molecularly consists of a spherical part to which the drug binds, branch-like structures with positive electrical charge and a compound called peg.
Since the cartel has a negative charge, the positive charges of the nanocarrier cause it to adhere to the texture. PEG, on the other hand, allows it to break through the cartilage and reach the chandrosites.
According to the newspaper La Vanguardardia, which is a publication of the magazine
Science Transsetional Medicine, The scientists added a drug called IGF-1 to the nanocarrier which stimulates the production of cartilage and the survival and growth of chandrosites.
To test the strategy, they injected the nanocarrier with the drug at the knee joints of rats that had ostiotarthritis of a mischief. The treatment reduces cartilage, inflammation and the appearance of bone alterations that are ostiarthritis. In comparison with the injection of IGF-1, only the combination with the nanocarrier multiplied by ten half-life of the drug in the joints. In addition, this was concentrated in significant concentrations in the cartilage for three days, so potentially a biweekly or monthly injection would be sufficient.